Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | CTSK | P43235 | 6/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14737659 | 1.00 | KMT2A (0.53) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL9998174 | 1.00 | KMT2A (0.53) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL25413076 | 0.84 | KMT2A (0.51) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL25413081 | 0.84 | KMT2A (0.51) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL7403325 | 0.84 | KMT2A (0.51) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL26419810 | 0.83 | KMT2A (0.53) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL28827213 | 0.83 | KMT2A (0.53) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL10841914 | 0.83 | KMT2A (0.53) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL31517881 | 0.83 | KMT2A (0.56) | KMT2ACTSSCTSKCA1CA2 | |
| SCHEMBL2390418 | 0.83 | KMT2A (0.56) | KMT2ACTSSCTSKCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102112449-A | Phenyl or pyridinyl substituted indazoles derivatives | ASTRAZENECA AB | 2011-06-29 | — | — | CN | disclosed |
| US-20100080786-A1 | Phenyl or Pyridinyl Substituted Indazoles Derivatives | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080786-A1 | Phenyl or Pyridinyl Substituted Indazoles Derivatives | CYP3A5, CYP3A43, ABCB1 | KMT2A 4465/4885CTSS 3335/4885CTSK 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.